Clinical Trials Logo

Stage IV Prostate Cancer AJCC v8 clinical trials

View clinical trials related to Stage IV Prostate Cancer AJCC v8.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05034562 Withdrawn - Clinical trials for Metastatic Prostate Carcinoma

Gallium-68 PSMA-11 PET in Participants With Prostate Cancer

Start date: September 26, 2022
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well gallium-68 PSMA-11 PET/CT or PET/MRI works in finding prostate cancer cells that have come back (recurrent) in patients with prostate cancer. Gallium-68 PSMA-11 is a type of radioactive compound, called a radiotracer, which is injected in the vein and can accumulate in tumor cells to generate a signal detected by PET/CT or PET/MRI imaging. This may help researchers in finding recurrent prostate cancer cells in patients with prostate cancer.

NCT ID: NCT04585932 Withdrawn - Clinical trials for Metastatic Prostate Carcinoma

Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study

Start date: November 24, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well androgen deprivation therapy and apalutamide with or without radiation therapy works for the treatment of prostate cancer that has a rise in the blood level of prostate-specific antigen (PSA) and has come back after treatment with surgery or radiation (biochemically recurrent). Androgens can cause the growth of prostate tumor cells. Apalutamide may help fight prostate cancer by blocking the use of androgens by the tumor cells. Androgen deprivation therapy drugs, leuprolide or degarelix, work to lower the amount of androgen in the body, also preventing the tumor cells from growing. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving radiation therapy with apalutamide and androgen deprivation therapy may help to control prostate cancer that has come back in only a few (up to 5) spots in the body.

NCT ID: NCT03709550 Withdrawn - Clinical trials for Castration-Resistant Prostate Carcinoma

Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Start date: April 15, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and best dose of decitabine and how well it works when given together with enzalutamide in treating patients with castration resistant prostate cancer that has spread to other places in the body. Androgen can cause the growth of prostate cancer cells. Drugs, such as enzalutamide, may lessen the amount of androgen made by the body. Decitabine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving decitabine and enzalutamide may work better in treating participants with castration resistant prostate cancer.